| mRNA |
GSK4112 |
CTRPv2 |
pan-cancer |
AAC |
0.0058 |
0.9 |
| mRNA |
prochlorperazine |
CTRPv2 |
pan-cancer |
AAC |
-0.0057 |
0.9 |
| mRNA |
BRD9876 |
CTRPv2 |
pan-cancer |
AAC |
0.0058 |
0.9 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0051 |
0.9 |
| mRNA |
Bortezomib |
CTRPv2 |
pan-cancer |
AAC |
-0.0052 |
0.9 |
| mRNA |
PD-0325901 |
GDSC1000 |
pan-cancer |
AAC |
0.0054 |
0.9 |
| mRNA |
BRD-A02303741 |
CTRPv2 |
pan-cancer |
AAC |
0.0058 |
0.9 |
| mRNA |
Camptothecin |
GDSC1000 |
pan-cancer |
AAC |
-0.0055 |
0.9 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0047 |
0.9 |
| mRNA |
MLN2238 |
CTRPv2 |
pan-cancer |
AAC |
0.0051 |
0.9 |